---
category: news
title: "Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma"
excerpt: "PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADRÂ® artificial intelligence (\"A.I.\") platform"
publishedDateTime: 2020-12-17T12:00:00Z
originalUrl: "https://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration-with-world-leading-brain-cancer-program-at-johns-hopkins-to-further-develop-lp-184-as-therapy-for-glioblastoma-301194949.html"
webUrl: "https://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration-with-world-leading-brain-cancer-program-at-johns-hopkins-to-further-develop-lp-184-as-therapy-for-glioblastoma-301194949.html"
type: article
quality: 15
heat: 15
published: false

provider:
  name: PR Newswire
  domain: prnewswire.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg?p=facebook"
    width: 939
    height: 491
    isCached: true

secured: "Vk9kRblZPpUeTDwRZa7Ln35gfMoVXqXBCyIYrhVpxgU3cN8O01rvdiDpThWiVsCbdhV/M6bP5ws5bTQCekgv+cN4ID/y7m+tGVA4MuYbjqvGwoW9lB1JfQiBpAVOvBV1EiHOpXohxYaK0oOrU8ZPak4BRtEi30sZeWgK5NEAqjOSL6DteLYFhOIZUNmVnaXvMGgQaEu9hx5CMTMZqdIvQOEbISL6M+G0ZGMTZ7EyTeWji0+lkXzoiyjvWcXH386osh/aOvZayMJ/Macltdeq0050naSw+GCHmS0bJ/S7uP0M3bBCwD/0Pf7YvP5DvrwePNr9WkjRYVrNViA3qzjU/g3xmGvjGfxdTagRclAmgLM=;PQfYuiY5+i1ZVMSF+a7LaQ=="
---

